History
# Registration date Revision Id
2 2021-06-06, 1400/03/16 186392
1 2019-05-05, 1398/02/15 88850
Changes made to previous revision
  • Help:

    Red color represents old content. It may be empty showing addition in the new version.
    Green color represents new content. It may be empty showing deletion in the new version.

    Inline Side by side
    Added new contents, deleted old contents, contents that are not changed.
    New table contents New table contents
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    Added new contents, contents that are not changed.
    Deleted old contents, contents that are not changed.
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    New table contents New table contents
    Unchanged contents Unchanged contents
  • Protocol summary

    Investigation of anti-inflammatory effect of Boswellia resin extract on inflammatory factors in ischemic stroke patients
    Investigation of anti-inflammatory effect of strowell capsules on inflammatory factors in ischemic stroke patients
    تعیین اثر ضدالتهابی عصاره صمغ کندر، بر فاکتورهای التهابی در بیماران سکته ایسکمیک
    تعیین اثر ضدالتهابی کپسول strowell، بر فاکتورهای التهابی در بیماران سکته ایسکمیک
    شرایط ورود به مطالعه: سن در محدوده 40-80 سال باشد؛ آزمون بالینی NIHSS در زمان پذیرش بایستی 4-20 باشد؛ شاخص توده بدنی نیز 20-25 باشد و علائم بالینی نورولوژیکی تائید شده با MRI شرایط عدم ورود به مطالعه: سکته هموراژیک؛ سابقه حساسيت به داروهای NSAIDs؛ سابقه خونریزی گوارشی؛ نارسايي حاد و مزمن کليوی و کبدی؛ بيماری روماتولوژيک و يا اتوايميون؛ سکته قلبی در 48 ساعت گذشته؛ سابقه سکته مغزی قبلی؛ حاملگی یا شیردهی؛ سرطان؛ ابتلا به هرگونه بیماری التهابی دیگر در حین نمونه گیری و بیماری که tPA دریافت کرده باشد
    شرایط ورود به مطالعه: سن در محدوده 40-80 سال باشد؛ آزمون بالینی NIHSS در زمان پذیرش بایستی 4-20 باشد؛ شاخص توده بدنی نیز 20-25 باشد و علائم بالینی نورولوژیکی تائید شده با MRI شرایط عدم ورود به مطالعه: سکته هموراژیک؛ سابقه حساسيت به داروهای NSAIDs؛ سابقه خونریزی گوارشی؛ نارسايي حاد و مزمن کليوی و کبدی؛ بيماری روماتولوژيک و يا اتوايميون؛ سکته قلبی در 48 ساعت گذشته؛ سابقه سکته مغزی قبلی؛ حاملگی یا شیردهی؛ سرطان؛ ابتلا به هرگونه بیماری التهابی دیگر در حین نمونه گیری و بیماری که tPA دریافت کرده باشد
    Boswellia resin extract receiving group Placebo group
    strowell capsules receiving group Placebo group
    گروه دریافت کننده عصاره صمغ کندر گروه دریافت کننده پلاسبو
    گروه دریافت کننده کپسول های strowell گروه دریافت کننده پلاسبو
  • General information

    empty
    Due to publishing the results of the study under the brand name Strowell, title has been modified accordingly.
    empty
    از آنجایی که نتایج مطالعه حاضر تحت نام strowell ثبت بین المللی شده است، لذا عنوان مطالعه با ذکر این نام اصلاح می گردد.
    Circulatory Cytokine Profiles of Ischemic Stroke Patients after Treatment with Boswellia Resin Extract
    Circulatory Cytokine Profiles of Ischemic Stroke Patients after Treatment with strowell capsules
    بررسی تاثیرات ضدالتهابی عصاره صمغ کندر بر غلظت‏ فاکتورهای التهابی پلاسمایی ، بیماران سکته ایسکمیک،
    بررسی تاثیرات ضدالتهابی کپسول strowell بر غلظت‏ فاکتورهای التهابی پلاسمایی ، بیماران سکته ایسکمیک،
    Investigation of Anti-inflammatory Effects of Boswellia Resin Extract on Plasma Inflammatory Factors in Ischemic Stroke Patients: A Randomized, Double-blind Placebo-controlled Trial
    Investigation of Anti-inflammatory Effects of strowell capsules on Plasma Inflammatory Factors in Ischemic Stroke Patients: A Randomized, Double-blind Placebo-controlled Trial
    بررسی تاثیرات ضدالتهابی عصاره صمغ کندر بر غلظت‏ فاکتورهای التهابی پلاسمایی در بیماران سکته ایسکمیک، کارآزمایی بالینی تصادفی دو سو کور
    بررسی تاثیرات ضدالتهابی کپسول strowell بر غلظت‏ فاکتورهای التهابی پلاسمایی در بیماران سکته ایسکمیک، کارآزمایی بالینی تصادفی دو سو کور
    Patient allocation and sequencing are done blindly. All the members of the staff who are involved in performing the enrollment, physicians, nurses and the investigation team as well as patients and their guardians, are masked. The research group is uninformed of drug and/or placebo prescription and its dosage. Codes will be written on the sealed envelopes and the medication bottles. Following patient assessment by the doctor, according to the admission sequence, the envelopes with the same number will be opened. Subsequently, the patients are going to be handed a bottle that could be the drug or placebo based on the assigned code. Therefore, the patient is unbeknownst whether the intervention is Boswellia resin extract or the placebo.
    Patient allocation and sequencing are done blindly. All the members of the staff who are involved in performing the enrollment, physicians, nurses and the investigation team as well as patients and their guardians, are masked. The research group is uninformed of drug and/or placebo prescription and its dosage. Codes will be written on the sealed envelopes and the medication bottles. Following patient assessment by the doctor, according to the admission sequence, the envelopes with the same number will be opened. Subsequently, the patients are going to be handed a bottle that could be the drug or placebo based on the assigned code. Therefore, the patient is unbeknownst whether the intervention is strowell capsules or the placebo.
    بیماران و همراهان ایشان، تمامی افرادی که در ثبت نام بیماران درگیرند، پزشکان، پرستاران و هر کسی که در فرآیند درمان و مراقبت با بیمار در ارتباط است و تیم محققان همگی نسبت به تجویز و مصرف دارو و یا دارو نما کور نگه داشته می شوند. ترتیب ورود بیمار بر روی پاکتهای مهر وموم شده واجد کد بیمار ثبت میگردد. روی بطری های دارو کدها نیز ثبت میگردد. پس از اینکه بیمار توسط پزشک از لحاظ معیارهای ورود به مطالعه مورد بررسی قرار گرفت، بر حسب ترتیب مراجعه پاکت مورد نظر باز میشود و کد مربوط به مداخله مشخص میگردد. بر اساس کد، بطری همان کد (دارو یا دارونما) به بیمار داده میشود. بدین ترتیب بیمار از اینکه دارو یا دارونما دریافت می کند، بی اطلاع است.
    بیماران و همراهان ایشان، تمامی افرادی که در ثبت نام بیماران درگیرند، پزشکان، پرستاران و هر کسی که در فرآیند درمان و مراقبت با بیمار در ارتباط است و تیم محققان همگی نسبت به تجویز و مصرف دارو و یا دارو نما کور نگه داشته می شوند. ترتیب ورود بیمار بر روی پاکتهای مهر وموم شده واجد کد بیمار ثبت میگردد. روی بطری های دارو کدها نیز ثبت میگردد. پس از اینکه بیمار توسط پزشک از لحاظ معیارهای ورود به مطالعه مورد بررسی قرار گرفت، بر حسب ترتیب مراجعه پاکت مورد نظر باز میشود و کد مربوط به مداخله مشخص میگردد. بر اساس کد، بطری همان کد (دارو یا دارونما) به بیمار داده میشود. بدین ترتیب بیمار از اینکه کپسول های strowell یا دارونما دریافت می کند، بی اطلاع است.
  • Primary outcomes

    #1
    At the commencement of the investigation and after taking the Boswellia resin extract
    At the commencement of the investigation and after taking the strowell capsules
    ابتدای مطالعه و پس از مصرف عصاره صمغ کندر
    ابتدای مطالعه و پس از مصرف کپسول های strowell
  • Intervention groups

    #1
    Intervention group: Boswellia Resin extract receiving group, 1 month, 3 times/day, Oral Administration (800 mg)
    Intervention group: strowell capsules receiving group, 1 month, 3 times/day, Oral Administration (800 mg)
    گروه مداخله: گروه دریافت کننده عصاره صمغ کندر، به مدت یک ماه، سه بار در روز، خوراکی (800 میلی گرم)
    گروه مداخله: گروه دریافت کننده کپسول strowell، به مدت یک ماه، سه بار در روز، خوراکی (800 میلی گرم)

Protocol summary

Study aim
Investigation of anti-inflammatory effect of strowell capsules on inflammatory factors in ischemic stroke patients
Design
Two arm parallel group randomized double-blind placebo-controlled trial
Settings and conduct
The trial is performed in Imam Hossein and Imam Khomeini Hospitals based on double-blind block randomization. All the people involved in the caregiving and treatment of the patients including companions, physicians, nurses and investigators are unbeknownst of the type of intervention.
Participants/Inclusion and exclusion criteria
Inclusion criteria: The inclusion age should be in 40-80 years range; National Institute of Health Stroke Scale (NIHSS) range is 4-20; and that of Body mass index (BMI) is 20-25. Focal neurological signs are confirmed by the Magnetic Resonance Imaging (MRI). Exclusion criteria: hemorrhagic stroke; history of Nonsteroidal Anti-inflammatory Drugs(NSAID) allergic response; history of gastrointestinal bleeding; kidney and liver failure; rheumatic and autoimmune diseases, myocardial infarction within previous 48 hours; previous stroke; pregnancy or lactation; malignancies; various other inflammatory diseases during the trial and those patients who have received tissue plasminogen activator (tPA).
Intervention groups
strowell capsules receiving group Placebo group
Main outcome variables
"Stroke intensity" "Blood Inflammatory markers"

General information

Reason for update
Due to publishing the results of the study under the brand name Strowell, title has been modified accordingly.
Acronym
IRCT registration information
IRCT registration number: IRCT20170315033086N5
Registration date: 2019-05-05, 1398/02/15
Registration timing: retrospective

Last update: 2021-06-13, 1400/03/23
Update count: 1
Registration date
2019-05-05, 1398/02/15
Registrant information
Name
Saeed Karima
Name of organization / entity
Shahid Beheshti University of Medical Sciences (SBMU)
Country
Iran (Islamic Republic of)
Phone
+98 21 9666 1028
Email address
karima@sbmu.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2017-05-01, 1396/02/11
Expected recruitment end date
2018-08-02, 1397/05/11
Actual recruitment start date
2017-06-25, 1396/04/04
Actual recruitment end date
2018-12-01, 1397/09/10
Trial completion date
2019-02-20, 1397/12/01
Scientific title
Investigation of Anti-inflammatory Effects of strowell capsules on Plasma Inflammatory Factors in Ischemic Stroke Patients: A Randomized, Double-blind Placebo-controlled Trial
Public title
Circulatory Cytokine Profiles of Ischemic Stroke Patients after Treatment with strowell capsules
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Diagnosis, based on neurological diagnostic signs and confirmed by Magnetic Resonance Imaging (MRI) National Institutes of Health Stroke Scale (NIHSS) should be in 4 - 20 range at the time of admission. Body mass index (BMI) should be in 20-25 range No inflammatory diseases
Exclusion criteria:
Hemorrhagic stroke transient ischemic attack (TIA) History of gastrointestinal bleeding History of sensitivity to NSIADs Previous stroke Myocardial infarction within the previous 48 hours Kidney and liver failure Immunosuppressive medications Stroke patients who have received tissue plasminogen activator (tPA). Rheumatoid and autoimmune diseases Malignancies Pregnancy or lactation
Age
From 40 years old to 80 years old
Gender
Both
Phase
2
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 80
Actual sample size reached: 43
Randomization (investigator's opinion)
Randomized
Randomization description
Randomization is designed based on four-sized block randomization procedure. A non-ordered computer sequence list including the patient-assigned code and the order of recruitment is generated by an epidemiologist. Given the block size of 4, there are 6 possible ways to equally assign participants to each treatment group. Therefore recruitment of participants to each treatment category is randomized and unpredictable. Following this randomization, an equal number of participants is randomly assigned to each treatment group.
Blinding (investigator's opinion)
Double blinded
Blinding description
Patient allocation and sequencing are done blindly. All the members of the staff who are involved in performing the enrollment, physicians, nurses and the investigation team as well as patients and their guardians, are masked. The research group is uninformed of drug and/or placebo prescription and its dosage. Codes will be written on the sealed envelopes and the medication bottles. Following patient assessment by the doctor, according to the admission sequence, the envelopes with the same number will be opened. Subsequently, the patients are going to be handed a bottle that could be the drug or placebo based on the assigned code. Therefore, the patient is unbeknownst whether the intervention is strowell capsules or the placebo.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Shahid Beheshti University of Medical Sciences, School of Medicine
Street address
Ground floor, medical faculty, Koodakyar Alley, Daneshjoo Blvd, Velenjak, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1985717434
Approval date
2017-01-03, 1395/10/14
Ethics committee reference number
IR.SBMU.MSP.REC.1395.409

Health conditions studied

1

Description of health condition studied
Ischemic stroke
ICD-10 code
I63.9
ICD-10 code description
Cerebral infarction, unspecified

Primary outcomes

1

Description
Stroke intensity
Timepoint
At the commencement of the investigation and after taking the strowell capsules
Method of measurement
NIH Stroke Scale questionnaire for quantifying stroke severity (11 items are included, level of consciousness, horizontal eye movement, visual field test, facial palsy, motor arm and motor leg, limb ataxia, sensory, language, speech, extinction and inattention)

2

Description
Pro- and anti-inflammatory plasma markers
Timepoint
At the investigation commencement and after the intervention
Method of measurement
ELISA assay kit

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: strowell capsules receiving group, 1 month, 3 times/day, Oral Administration (800 mg)
Category
Treatment - Drugs

2

Description
Control group: Placebo group,1 month, 3 times/day, Oral (800 mg)
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Imam Hossein Hospital
Full name of responsible person
Behnam Safarpour Lima
Street address
Shahid Madani St., Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1617948615
Phone
+98 21 7343 3000
Email
info@ehmc.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Behnam Safarpour Lima
Street address
Shahid Madani St., Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1617948615
Phone
+98 21 7343 3000
Email
info@ehmc.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shahid Beheshti University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Other

Person responsible for general inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Behnam Safarpour Lima
Position
Associate professor
Latest degree
Medical doctor
Other areas of specialty/work
Neurology
Street address
Shahid Madani St., Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1617948615
Phone
+98 21 7343 3000
Email
info@ehmc.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Behnam Safarpour Lima
Position
Associate professor
Latest degree
Medical doctor
Other areas of specialty/work
Neurology
Street address
Shahid Madani St., Tehran,
City
Tehran
Province
Tehran
Postal code
1617948615
Phone
+98 21 7343 3000
Email
info@ehmc.ir

Person responsible for updating data

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Behnam Safarpour Lima
Position
Associate professor
Latest degree
Medical doctor
Other areas of specialty/work
Neurology
Street address
Shahid Madani St., Tehran
City
Tehran
Province
Tehran
Postal code
1617948615
Phone
+98 21 7343 3000
Email
info@ehmc.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Not applicable
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Not applicable
Title and more details about the data/document
collected de-identified IPD, IPD collected for the primary outcome measure only
When the data will become available and for how long
De-identified data will be available starting from April, 2021
To whom data/document is available
Academics employed at various research/university institutions and the industry.
Under which criteria data/document could be used
No specific condition are specified.
From where data/document is obtainable
Behnam Safarpour Lima, Shahid Madani St., Tehran, Iran, Tel: +982173433000 Mob. 091229811576
What processes are involved for a request to access data/document
1- The applicant would be asked to provide a written formal request letter, containing the importance of the data and the project processes. 2- Following the receipt of request letter, the data would be provided in no more than two weeks.
Comments
Loading...